Revolution Medicines Management
Management criteria checks 3/4
Revolution Medicines' CEO is Mark Goldsmith, appointed in Nov 2014, has a tenure of 9.5 years. total yearly compensation is $10.41M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth $23.88M. The average tenure of the management team and the board of directors is 6 years and 7.4 years respectively.
Key information
Mark Goldsmith
Chief executive officer
US$10.4m
Total compensation
| CEO salary percentage | 6.1% |
| CEO tenure | 9.5yrs |
| CEO ownership | 0.4% |
| Management average tenure | 6yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Apr 12Revolution Medicines Is Hard To Understand
Feb 01Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation
Aug 09
Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates
May 13We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
Apr 02We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Dec 20We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Sep 15Revolution Medicines promotes Jack Anders to CFO
Sep 02New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)
Aug 10Revolution Medicines to raise up to $200M in stock offering
Jul 19Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 11We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Mar 31Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Dec 16What Does The Future Hold For Revolution Medicines, Inc. (NASDAQ:RVMD)? These Analysts Have Been Cutting Their Estimates
Aug 17Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Aug 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$10m | US$631k | -US$436m |
| Sep 30 2023 | n/a | n/a | -US$331m |
| Jun 30 2023 | n/a | n/a | -US$296m |
| Mar 31 2023 | n/a | n/a | -US$259m |
| Dec 31 2022 | US$7m | US$607k | -US$249m |
| Sep 30 2022 | n/a | n/a | -US$245m |
| Jun 30 2022 | n/a | n/a | -US$224m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$8m | US$581k | -US$187m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$143m |
| Mar 31 2021 | n/a | n/a | -US$126m |
| Dec 31 2020 | US$2m | US$554k | -US$110m |
| Sep 30 2020 | n/a | n/a | -US$95m |
| Jun 30 2020 | n/a | n/a | -US$85m |
| Mar 31 2020 | n/a | n/a | -US$71m |
| Dec 31 2019 | US$5m | US$504k | -US$62m |
| Sep 30 2019 | n/a | n/a | -US$57m |
| Dec 31 2018 | US$1m | US$490k | -US$49m |
Compensation vs Market: Mark's total compensation ($USD10.41M) is about average for companies of similar size in the US market ($USD8.43M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
CEO
Mark Goldsmith (61 yo)
9.5yrs
Tenure
US$10,411,247
Compensation
Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Par...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 9.5yrs | US$10.41m | 0.36% $ 23.9m | |
| Chief Financial Officer | 5.8yrs | US$3.05m | 0.024% $ 1.6m | |
| Chief Operating Officer | 5.6yrs | US$4.39m | 0.027% $ 1.8m | |
| President of Research & Development | 7.2yrs | US$4.39m | 0.098% $ 6.5m | |
| Executive Vice President of Development | 6.2yrs | US$3.23m | 0.013% $ 862.6k | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Academic Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.4yrs | no data | no data | |
| Chief Information Officer | no data | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior VP | 1.7yrs | no data | 0.0032% $ 211.8k |
6.0yrs
Average Tenure
52yo
Average Age
Experienced Management: RVMD's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 9.5yrs | US$10.41m | 0.36% $ 23.9m | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.4yrs | no data | no data | |
| Senior Advisor & Member of Scientific Advisory Board | 7.4yrs | no data | no data | |
| Lead Independent Director | 9.5yrs | US$510.63k | 1.36% $ 91.2m | |
| Senior Advisor & Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Senior Advisor & Member of Scientific Advisory Board | 7.4yrs | no data | no data | |
| Independent Director | 1.8yrs | US$489.99k | 0.031% $ 2.1m | |
| Independent Director | 6.2yrs | no data | no data | |
| Independent Director | 9.2yrs | US$483.78k | 0.038% $ 2.5m | |
| Senior Advisor & Member of Scientific Advisory Board | 7.4yrs | no data | no data |
7.4yrs
Average Tenure
51yo
Average Age
Experienced Board: RVMD's board of directors are considered experienced (7.4 years average tenure).